Baxter's influenza vaccines are produced using the company's unique Vero-cell technology which the potential to significantly reduce production time compared to traditional vaccine production methods using embryonated hens' eggs.
Baxter also produces leading vaccines for prevention of meningitis C, a highly infectious disease characterised by rapid onset of life-threatening and debilitating symptoms, and tick-borne encephalitis, a potentially fatal disease common in Europe.
Pandemic Influenza vaccine
Baxter's Pandemic Influenza vaccine, named Celvapan was the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorisation in the European Union.
Tick-borne Encephalitis (TBE) vaccine
TicoVac is licensed to prevent tick borne encephalitis infection in adults and children.